329 related articles for article (PubMed ID: 30293967)
1. Pharmacological inhibition of autophagy by 3-MA attenuates hyperuricemic nephropathy.
Bao J; Shi Y; Tao M; Liu N; Zhuang S; Yuan W
Clin Sci (Lond); 2018 Nov; 132(21):2299-2322. PubMed ID: 30293967
[TBL] [Abstract][Full Text] [Related]
2. Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy.
Shi Y; Tao M; Ma X; Hu Y; Huang G; Qiu A; Zhuang S; Liu N
Cell Death Dis; 2020 Jun; 11(6):467. PubMed ID: 32555189
[TBL] [Abstract][Full Text] [Related]
3. EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.
Liu N; Wang L; Yang T; Xiong C; Xu L; Shi Y; Bao W; Chin YE; Cheng SB; Yan H; Qiu A; Zhuang S
J Am Soc Nephrol; 2015 Nov; 26(11):2716-29. PubMed ID: 25788532
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.
Liu N; Xu L; Shi Y; Fang L; Gu H; Wang H; Ding X; Zhuang S
Oncotarget; 2017 May; 8(20):33807-33826. PubMed ID: 28442634
[TBL] [Abstract][Full Text] [Related]
5. Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling.
Ren Q; Tao S; Guo F; Wang B; Yang L; Ma L; Fu P
Phytomedicine; 2021 Jul; 87():153552. PubMed ID: 33994251
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid attenuates renal fibrosis through the induction of autophagy.
Kawaoka K; Doi S; Nakashima A; Yamada K; Ueno T; Doi T; Masaki T
Clin Exp Nephrol; 2017 Oct; 21(5):771-780. PubMed ID: 27928635
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice.
Singh SP; Tao S; Fields TA; Webb S; Harris RC; Rao R
Dis Model Mech; 2015 Aug; 8(8):931-40. PubMed ID: 26092126
[TBL] [Abstract][Full Text] [Related]
8. Zishen Qingre Tongluo Formula Improves Renal Fatty Acid Oxidation and Alleviated Fibrosis via the Regulation of the TGF-
Liu P; Wang C; Wang Y; Zhang H; Liu B; Qiu X
Biomed Res Int; 2021; 2021():2793823. PubMed ID: 34938805
[TBL] [Abstract][Full Text] [Related]
9. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis.
Yan Y; Ma L; Zhou X; Ponnusamy M; Tang J; Zhuang MA; Tolbert E; Bayliss G; Bai J; Zhuang S
Kidney Int; 2016 Jan; 89(1):68-81. PubMed ID: 26444028
[TBL] [Abstract][Full Text] [Related]
10. Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis.
Hu Y; Shi Y; Chen H; Tao M; Zhou X; Li J; Ma X; Wang Y; Liu N
Front Immunol; 2022; 13():858494. PubMed ID: 35309342
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of Src family kinases attenuates hyperuricemic nephropathy.
Xiong C; Deng J; Wang X; Hou Q; Zhuang S
Front Pharmacol; 2024; 15():1352730. PubMed ID: 38576481
[TBL] [Abstract][Full Text] [Related]
12. Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy.
Pan J; Shi M; Li L; Liu J; Guo F; Feng Y; Ma L; Fu P
Biomed Pharmacother; 2019 Jan; 109():1802-1808. PubMed ID: 30551434
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis.
Xiong C; Masucci MV; Zhou X; Liu N; Zang X; Tolbert E; Zhao TC; Zhuang S
Oncotarget; 2016 Oct; 7(43):69291-69308. PubMed ID: 27732564
[TBL] [Abstract][Full Text] [Related]
14. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species.
Samarakoon R; Dobberfuhl AD; Cooley C; Overstreet JM; Patel S; Goldschmeding R; Meldrum KK; Higgins PJ
Cell Signal; 2013 Nov; 25(11):2198-209. PubMed ID: 23872073
[TBL] [Abstract][Full Text] [Related]
15. LncRNA ENST00000453774.1 contributes to oxidative stress defense dependent on autophagy mediation to reduce extracellular matrix and alleviate renal fibrosis.
Xiao X; Yuan Q; Chen Y; Huang Z; Fang X; Zhang H; Peng L; Xiao P
J Cell Physiol; 2019 Jun; 234(6):9130-9143. PubMed ID: 30317629
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction.
Yang J; Dai C; Liu Y
Am J Pathol; 2003 Aug; 163(2):621-32. PubMed ID: 12875981
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats.
Xiong C; Deng J; Wang X; Shao X; Zhou Q; Zou H; Zhuang S
Front Pharmacol; 2021; 12():636154. PubMed ID: 33664670
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy.
Shi M; Guo F; Liao D; Huang R; Feng Y; Zeng X; Ma L; Fu P
Eur J Pharmacol; 2020 Nov; 887():173570. PubMed ID: 32949603
[TBL] [Abstract][Full Text] [Related]
19. Blockade of ERK1/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy.
Tao M; Shi Y; Tang L; Wang Y; Fang L; Jiang W; Lin T; Qiu A; Zhuang S; Liu N
Am J Physiol Renal Physiol; 2019 Apr; 316(4):F660-F673. PubMed ID: 30648910
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis.
Jiao B; An C; Tran M; Du H; Wang P; Zhou D; Wang Y
Front Immunol; 2021; 12():735014. PubMed ID: 34512669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
